ACRS - アクラリス・セラピュ―ティクス （Aclaris Therapeutics Inc.）ACRSのニュース
Aclaris Therapeutics Inc. (NASDAQ:ACRS) Falls -0.48%, But An Additional Plunge May Follow. 2022/04/30 17:00:00 Marketing Sentinel
In last trading session, Aclaris Therapeutics Inc. (NASDAQ:ACRS) saw 0.36 million shares changing hands with its beta currently measuring 0.53. Company’s recent per share price level of $12.32 trading at -$0.06 or -0.48% at ring of the bell on the day assigns it a market valuation of $790.94M. That closing price of ACRS’s stock is … Aclaris Therapeutics Inc. (NASDAQ:ACRS) Falls -0.48%, But An Additional Plunge May Follow. Read More »
Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3M 2022/02/24 12:02:50 Seeking Alpha
Aclaris Therapeutics press release (ACRS): Q4 GAAP EPS of -$0.37 misses by $0.01.Revenue of $1.5M (-5.1% Y/Y) misses by $0.3M.
Aclaris Therapeutics Q4 2021 Earnings Preview (NASDAQ:ACRS) 2022/02/23 16:07:39 Seeking Alpha
Aclaris Therapeutics (NASDAQ:ACRS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.36 and the consensus
There Is A Lot Of Upside Potential For Aclaris Therapeutics Inc.(NASDAQ: ACRS) 2022/02/12 13:00:00 Stocks Register
Aclaris Therapeutics Inc. (NASDAQ:ACRS) price on Friday, February 11, rose 0.87% above its previous days close as an upside momentum from buyers pushed the stocks value to $12.71. A look at the stocks price movement, the close in the last trading session was $12.60, moving within a range at $12.43 and $13.10. The beta value There Is A Lot Of Upside Potential For Aclaris Therapeutics Inc.(NASDAQ: ACRS) Read More »
Did Hedge Funds Catch A Break With Aclaris Therapeutics, Inc. (ACRS)? 2022/02/06 21:33:03 Insider Monkey
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Aclaris price target raised at Jefferies citing significant stock moving event 2021/07/23 19:37:32 Seeking Alpha
Hair Loss Treatment Market 2021-2028 | Booming Overall | Generated Opportunities - Viviscal, Cipla Limited, Aclaris Therapeutics, Merck & Co, Daiichi-Sankyo Co., Ltd 2021/07/21 07:47:40 OpenPR
Hair loss can be caused by numerous disorders. Alopecia areata or hair loss begins after the onset of puberty. Alopecia is a common autoimmune disorder that often results in unpredictable hair loss on the scalp, face, and other areas of
Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape 2021/07/15 01:00:00 Benzinga
Los Angeles, July 14, 2021 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape The Hidradenitis Suppurativa pipeline landscape includes several therapies with different mechanisms of action currently being studied with great market potential. Ongoing scientific research has provided greater sophistication and a clearer understanding of the mechanisms of therapeutic interventions for Hidradenitis suppurativa. DelveInsight''s '' Hidradenitis Suppurativa Pipeline Insights '' report presents an exhaustive coverage of the available therapies, Hidradenitis Suppurativa emerging drug therapies in different phases of clinical development, key companies working to advance the Hidradenitis Suppurativa pipeline therapies, and the future market scope of the space. Some of the notable pointers extracted from the Hidradenitis Suppurativa (HS) Pipeline report: DelveInsight''s analysis depicts a robust Hidradenitis Suppurativa Pipeline with 25+ active players in the domain working on 25+ pipeline therapies.
Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021 2021/07/08 11:00:00 Intrado Digital Media
WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a virtual panel discussion at the William Blair Biotech Focus Conference 2021 titled Novel Targets for Autoimmune Diseases, on Thursday, July 15, 2021 at 11:00 a.m. ET. Management will be available July 15th throughout the day for virtual one-on-one meetings.
Hedge Funds Have Never Been This Bullish On Aclaris Therapeutics, Inc. (ACRS) 2021/07/06 14:13:01 Insider Monkey
Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright 2021/06/16 10:25:29 Smarter Analyst
In a report released today, Ram Selvaraju from H.C. The post Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst .
Analysts Offer Insights on Healthcare Companies: Chinook Therapeutics (KDNY), Aclaris Therapeutics (ACRS) and Translate Bio (TBIO) 2021/06/11 13:55:08 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chinook Therapeutics (KDNY), Aclaris Therapeutics The post Analysts Offer Insights on Healthcare Companies: Chinook Therapeutics (KDNY), Aclaris Therapeutics (ACRS) and Translate Bio (TBIO) appeared first on Smarter Analyst .
Aclaris Therapeutics prices $125M public stock offering 2021/06/10 14:51:50 Business Journals
The company said it may use a portion of the net proceeds to invest in or acquire additional businesses or technologies.
Hair Loss Treatment Market Is Booming Worldwide with Product development in future | Viviscal, Cipla Limited, Aclaris Therapeutics 2021/06/10 12:41:54 OpenPR
The global Hair Loss Treatment market which projected a CAGR of approximately +7% in the midst of the estimate time span of 2020-2027. Coherent Market Insights has added a new report to its database that qualifies an expressive and professional look